Europe News

Found 80,768 articles

• 

  Janssen Eyes Another Approval for Tremfya After Hitting Trial Endpoints

  6/14/2019

  Tremfya hit the mark in two late-stage psoriatic arthritis trials, setting the stage for another potential approval.
• 

  BioSpace Movers and Shakers, June 14

  6/14/2019

  Biotech and pharma companies strengthen their leadership teams and boards with new hires and appointments.

• Univar Solutions tops ICIS 2019 chemical distributors ranking in North America with $6.3bn in sales

  6/14/2019

  Univar Solutions tops the 10th ICIS Top 100 Chemical Distributors ranking in North America announced today.

• New Contract Research Organisation for Platelet Testing

  6/14/2019

  Platelet specialists Dr Natalia Dovlatova, Ann White and Bob Humphries announce the launch of their new company – ‘Platelet Services Limited’, which will be based in BioCity Nottingham, UK.

• Transgene launches a Rights Issue for an amount of up to €50 million

  6/14/2019

   Transgene (Euronext Paris: TNG) (“Transgene” or the “Company”), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, announces today the launch and terms of a share capital increase with shareholders’ preferential subscription rights for an amount of up to €50 million (issue premium included) (the “Rights Issue”).

• Faron Pharmaceuticals Oy: Final results from YODA study confirm previously reported findings

  6/14/2019

  Faron Pharmaceuticals Oy (AIM: FARN), the clinical stage biopharmaceutical company, today announces results from its pharmacokinetic/dynamic YODA study examining the administration of concomitant steroids and Traumakine in healthy volunteers.

• Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early

  6/14/2019

  Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the independent Data Monitoring Committee (“IDMC”) of the Phase III pivotal study of surufatinib in advanced neuroendocrine tumors – extra-pancreatic (“SANET-ep”) has completed a planned interim analysis.

• New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy

  6/14/2019

  Sandoz, a Novartis division and a global leader in biosimilars, today announced data from the Phase III ADMYRA trial demonstrating that the efficacy and safety of biosimilar Hyrimoz® (adalimumab)* matches that of the reference medicine adalimumab** with no clinically meaningful differences in patients with moderate-to-severe rheumatoid arthritis (RA) with inadequate response to disease modifying antirheumatic drugs (DMARDs), including methotrexate (MTX)1

• Peli BioThermal Launches Dublin Network Station & Service Centre

  6/14/2019

  Peli BioThermal, the global name in temperature controlled packaging, launched its new network station and service centre in Dublin, Ireland with an official opening ceremony at the facility dedicated to service, refurbish, repair and condition Peli BioThermal’s reusable Crēdo on Demand shippers.

• First Human Clinical Trial Results on the Anti-Aging Compound, Urolithin A, PUblished by Amazentis and Researchers From the EPFL and SIB

  6/14/2019

  Amazentis, an innovative life sciences company pioneering scientific breakthroughs in nutrition to manage health conditions linked to aging, announced today a collaborative publication in Nature Metabolism with scientists at the École Polytechnique Fédérale de Lausanne (EPFL) and the Swiss Institute of Bioinformatics (SIB) demonstrating the Company’s lead product, Urolithin A (UA), is safe, bioavailable and improves mitochondrial and cellular health in humans.

• UCB's Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients

  6/14/2019

  UCB announced new Phase 2b data on the company's key pipeline molecule, bimekizumab, that showed improvements in a range of important health-related domains and general well-being for patients with active ankylosing spondylitis.ii Results from this study, which evaluated multiple treatment doses, were shared for the first time today at the Annual European Congress of Rheumatology, in Madrid.

• BerGenBio Presents Preliminary Phase II Clinical Data at EHA 24: Bemcentinib in Combination With Low Dose Chemotherapy Yields Durable Responses in AML Patients Unfit for Intensive Chemotherapy

  6/14/2019

  BerGenBio ASA presents data showing significant efficacy in a Phase II clinical trial evaluating bemcentinib, a first-in-class selective oral AXL inhibitor, in combination with low-dose cytarabine as a potential new treatment regimen for AML patients unfit for intensive therapy.

• New Data Presented at 24th EHA Congress From Oncopeptides' Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)

  6/14/2019

  Oncopeptides AB, announced new data presented at the 24th Congress of the European Hematology Association in Amsterdam, including updated interim data from the ongoing phase 1/2 ANCHOR study and data from its phase 1/2 O-12-M1 study.

• Teledyne SP Devices Announces New 8-channel 10-bit Digitizer with 1 GS/s Sampling Rate

  6/14/2019

  Flexible multi-channel digitizer with high channel density and open FPGA

• Prometic Presents New Data on PBI-4050 and its Mechanism of Action on Kidney Fibrosis at the 56th ERA/EDTA Congress

  6/14/2019

  Prometic Life Sciences Inc. announced that four abstracts highlighting Prometic's progress in developing PBI-4050 as a potential treatment for both acute kidney injury and chronic kidney disease will be presented at the 56th Congress of the European Renal Association - European Dialysis and Transplant Association.

• Study Data Find Significant Differences In Exhaled Toxicants And Particles In Vapor Products Compared To Combustible Cigarettes

  6/14/2019

  Study presented at 6th Global Forum on Nicotine contrasts exhaled toxicants in vapor products versus combustible cigarettes

• Study Demonstrates Smokers Who Used Non-Tobacco-Flavored JUUL Products Were More Likely To Switch From Cigarettes Than Those Who Used Tobacco-Flavored JUUL Products

  6/14/2019

  Poster presented at 6th Global Forum on Nicotine, Warsaw, Poland

• 

  GSK Invests $67 Million to Co-Found Genomics Lab with University of California

  6/13/2019

  The Laboratory for Genomics Research will be funded by GSK up to $67 million over the five-year period and will include space for 24 full-time university employees and up to 14 full-time GSK staffers.
• 

  BioSpace Global Roundup, June 13

  6/13/2019

  Companies from across the globe share business and pipeline updates.

• InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum

  6/13/2019

  Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful skin ulcers